Navigation Links
BioSpecifics Technologies Corp. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Date:12/10/2012

NEW YORK, Dec. 10, 2012 /PRNewswire/ -- RetailInvestorConferences.com is pleased to announce that BioSpecifics Technologies Corp.'s (NASDAQ: BSTC) December 6th RetailInvestorConferences.com presentation is now available for on-demand viewing. BioSpecifics is a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia.

LINK:    www.retailinvestorconferences.com > red "register/ watch event now" button

BioSpecifics Technologies Corp.'s presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the "virtual trade booth" for the next three weeks.

BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. (Nasdaq GM: BSTC) is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. Injectable collagenase is currently marketed as XIAFLEX® in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord by Auxilium Pharmaceuticals, Inc. (Auxilium) and is approved for Dupuytren's contracture in the European Union and Canada. XIAFLEX is also in clinical development for the treatment of several additional promising indications: Auxilium recently submitted a supplemental Biologics License Application (sBLA) to the FDA for XIAFLEX for the potential treatment of Peyronie's disease based on positive results reported from its two Phase III clinical studies. Auxilium is also testing XIAFLEX for frozen shoulder syndrome (adhesive capsulitis) and cellulite in Phase IIa and Phase Ib clinical trials, respectively. BioSpecifics is currently managing the clinical development of XIAFLEX for the treatment of human lipoma and canine lipoma, which are both in Phase II clinical trials. Auxilium is currently partnered with Asahi Kasei Pharma Corporation for the development and commercialization of injectable collagenase for Dupuytren's contracture and Peyronie's disease in Japan and with Actelion Pharmaceuticals Ltd. for these same indications in Canada, Australia, Brazil and Mexico. Pfizer Inc. has marketing rights to XIAPEX® (the EU trade name for XIAFLEX) for Dupuytren's contracture in 46 countries in Eurasia through April 24, 2013.  For more information, please visit www.biospecifics.com.

About RetailInvestorConferences.com:

Since 2010, RetailInvestorConferences.com has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.


'/>"/>
SOURCE RetailInvestorConferences.com
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors
2. BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
3. BioSpecifics Technologies Corp. Reports Second Quarter 2012 Financial Results
4. BioSpecifics Technologies Corp. To Present at UBS Global Life Sciences Conference
5. BioSpecifics Technologies Corp. Reports Third Quarter 2012 Financial Results
6. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
7. UV Flu Technologies Expands Its International Footprint
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy
10. Hologic to Showcase 3D Mammography (Breast Tomosynthesis) and Other Advanced Womens Imaging Technologies at RSNA 2011, the Largest Radiology Show in the World
11. Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Looking for ... and cooking events company, offers one-of-a-kind gifts, ranging from gourmet cooking experiences to ... cuisine, and guests leave inspired with new cooking tips and techniques, thanks to ...
(Date:4/26/2017)... ... April 26, 2017 , ... Baltimore bio tech ... mail security screening solution at the National Postal Forum 2017 in Baltimore, Maryland, ... fast, highly accurate, easy to use and low cost threat detection solution for ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... As part ... the series will explore the laboratory testing for DIC in order to illuminate this ... disorder which can occur in hospitalized patients resulting in a high degree of morbidity ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... Physical Medicine & Rehabilitation, P.A. , proudly announced today that acclaimed physiatrist Matthew ... his duties on May 15, 2017. , Dr. Terzella completed his residency in ...
Breaking Biology Technology:
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed Anwar ... prestigious international IAIR Award for the most innovative high security ePassport and ... ... Maldives Immigration Controller General, Mr. Mohamed ... the right) have received the IAIR award for the "Most innovative high ...
(Date:3/23/2017)... 23, 2017 Research and Markets has announced ... & Trends - Industry Forecast to 2025" report to their ... The ... CAGR of around 8.8% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
Breaking Biology News(10 mins):